Perivascular Adipose Tissue Control of Insulin-Induced Vasoreactivity in Muscle Is Impaired in \( \text{db/db} \) Mice

Rick I. Meijer,1,2 Wineke Bakker,2 Caro-Lynn A.F. Alta,2 Pieter Sipkema,2 John S. Yudkin,1,3 Benoit Viollet,4,5,6 Erik A. Richter,7 Yvo M. Smulders,8 Victor W.M. van Hinsbergh,2 Erik H. Serné,1 and Etto C. Eringa2

Microvascular recruitment in muscle is a determinant of insulin sensitivity. Whether perivascular adipose tissue (PVAT) is involved in disturbed insulin-induced vasoreactivity is unknown, as are the underlying mechanisms. This study investigates whether PVAT regulates insulin-induced vasodilation in muscle, the underlying mechanisms, and how obesity disturbs this vasodilation. Insulin-induced vasoreactivity of resistance arteries was studied with PVAT from C57BL/6 or \( \text{db/db} \) mice. PVAT weight in muscle was higher in \( \text{db/db} \) mice compared with C57BL/6 mice. PVAT from C57BL/6 mice uncovered insulin-induced vasodilation; this vasodilation was abrogated with PVAT from \( \text{db/db} \) mice. Blocking adiponectin abolished the vaso dilator effect of insulin in the presence of C57BL/6 PVAT, and adiponectin secretion was lower in \( \text{db/db} \) PVAT. To investigate this interaction further, resistance arteries of \( \text{AMPK}^{2+/+} \) and \( \text{AMPK}^{2−/−} \) were studied. In \( \text{AMPK}^{2−/−} \) resistance arteries, insulin caused vasoconstriction in the presence of PVAT, and \( \text{AMPK}^{2−/−} \) resistance arteries showed a neutral response. On the other hand, inhibition of the inflammatory kinase Jun NH2-terminal kinase (JNK) in \( \text{AMPK}^{2−/−} \) resistant arteries, and insulin caused vasodilation in the absence of C57BL/6 PVAT, and adiponectin secretion was lower in \( \text{db/db} \) PVAT. 

Insulin’s vasoactive properties are affected through pathways shared with insulin’s metabolic effects (6). Insulin initiates both vasodilator and vasoconstrictor responses, the former through activation of insulin receptor substrate-1, leading to phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) and subsequent NO production. Vasoconstriction is achieved through extracellular signal–related kinase 1/2 (ERK1/2), which increases endothelin-1 activity (7). In lean, insulin-sensitive subjects, the net result of the balance between insulin-stimulated vasodilation and vasoconstriction is usually toward vasodilation (8). In obesity, the net result is shifted toward less vasodilation or even vasoconstriction, but how obesity leads to a blunted insulin-induced vasodilation has not been elucidated.

One of the mechanisms involved may be that obesity is associated with adipose tissue accumulation in ectopic locations, which may disturb microvascular function (9). The location of adipose tissue is one critical determinant for its function; another is its adipokine secretion profile (1). Adiponectin is a major adipokine of which secretion is altered in obesity (10,11), and it is related to insulin sensitivity and vascular function (12,13). Adiponectin has been proposed to mediate cross-talk between perivascular adipose tissue (PVAT) and vascular endothelium to contribute to the regulation of muscle perfusion (14). An important effector of adiponectin is 5′-AMP-activated protein kinase (AMPK), a regulator of metabolic homeostasis. AMPK is activated by adiponectin and, when activated by AICAR, enhances vasodilation and muscle perfusion (15). In obesity, the secretion of adiponectin changes, as well as numerous other adipokines, a major part of which are cytokines (1,7). Inflammatory cytokines can blunt insulin-stimulated vasoactivity (7), but it is unknown whether inhibition of inflammation can restore this effect.

Recently, interest in the role of deposits of PVAT in the regulation of microvascular function has increased. Adipokines affect insulin signaling in the vasculature, leading to a disturbed microvascular function (7,9,16–18). Nevertheless, the disturbance of microvascular function in obesity cannot be fully explained by circulating adipokine concentrations, which are mainly determined by the large subcutaneous and visceral adipose tissue depots (19). The concentrations of circulating adipokines are too low for biological effects on insulin-stimulated vasoactivity (9). An alternative source of adipokines is PVAT (9). PVAT may have a direct paracrine, and possibly vasocrine (i.e., from one vessel to downstream vessels), effect on the vasculature due to the inherent proximity to the vasculature (9,20). In humans, PVAT around the brachial artery is independently associated with insulin sensitivity (21). Additionally, PVAT exhibits an altered

O

bsity is associated with insulin resistance in all organs, including skeletal muscle and the vasculature. The increase of adipose tissue mass in obesity is associated with an altered adipokine secretion profile (1). However, the mechanisms through which this increase in adipose tissue mass leads to insulin resistance are not fully understood. One of these mechanisms may be modulation of insulin-induced vasoreactivity. Indeed, the ability of insulin to induce vasodilation in the muscle microcirculation is an important determinant for whole-body insulin sensitivity (2–5). Nevertheless, whether and how microvascular recruitment is controlled by adipose tissue are unclear.

From the 1Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands; the 2Laboratory for Physiology, VU University Medical Center, Amsterdam, the Netherlands; the 3Department of Medicine, University College London, London, U.K.; 4INSERM, U1016, Cochin Institute, Paris, France; the 5Centre National de la Recherche Scientifique, UMR8104, Paris, France; 6Paris Descartes University, Paris, France; and the 7Department of Exercise and Sport Sciences, University of Copenhagen, Copenhagen, Denmark.

Corresponding author: Etto C. Eringa, e.eringa@vumc.nl.

Received 16 November 2011 and accepted 1 August 2012.

DOI: 10.2337/db11-1603

R.L.M. and W.B. contributed equally to this study.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
adipokine profile compared with other adipose depots in obesity (10,11,22). PVAT can therefore be considered as a distinct adipose tissue depot. It is unknown whether PVAT affects insulin-induced vasoreactivity in the muscle microcirculation through secretion of adipokines.

Isolated adipokines are known to affect insulin-induced vasoreactivity, but few studies have investigated directly whether PVAT affects microvascular function. Previous studies have been targeted at the modulating effect of PVAT on the response to norepinephrine and acetylcholine in the aorta and larger arteries; PVAT has anticontractile effects in these vessels (23–25). Microvessels were investigated in only one study; however, as the microvessels were derived from subcutaneous adipose tissue, they do not control nutrient exchange (11). In muscle, the microcirculation controls nutrient exchange, but the effects of PVAT on muscle resistance arteries have never been studied. The direct effect of PVAT, as well as the potentially associated role of adiponectin and AMPK, on insulin-induced vasoreactivity in the lean and obese state remains unknown. Likewise, the role of inflammation in PVAT in insulin-induced vasoreactivity is not fully elucidated.

We hypothesized that PVAT affects insulin-induced vasoreactivity in isolated muscle resistance arteries, that it does so through adiponectin secretion, and that this effect of PVAT is blunted in obesity. Moreover, the underlying mechanisms, focusing particularly on the potential involvement of AMPKα2, and the signaling pathway molecule Akt, which is used as a marker of NO production, were examined. To assess whether inflammation impairs PVAT function, we studied the involvement of Jun NH2-terminal kinase (JNK), a mediator of inflammation.

**RESEARCH DESIGN AND METHODS**

**Animals.** This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (publication no. 85–23, revised 1986). All animal work was approved by the local ethics committee for animal experiments of the VU University Amsterdam and complied with Dutch government guidelines. Male C57BL/6N(Crl) (further indicated as C57BL/6) (Charles River, Amsterdam, the Netherlands), male db/db (Harlan, Zeist, the Netherlands), and AMPKα2−/− and AMPKα2−+/+ mice 10 weeks of age were killed by isoflurane overdose. To study the role of AMPK in insulin-induced vaso-reactivity, male C57BL/6N mice (back-crossed for >10 generations; Taconic, Gély, Denmark) with a deletion of the AMPKα2 (AMPKα2−/−) catalytic subunit gene, together with their AMPKα2−+/+ littermates, were generated as previously described (26).

**Weight of PVAT.** PVAT was dissected in one piece, free of surrounding connective tissue, from C57BL/6 (n = 6) and db/db (n = 6) mice and was quantified on a microbalance. Figure 1A gives an impression of the stretch of the dissected PVAT.

**Vasoreactivity experiments.** To study the insulin-induced vasoreactivity of resistance arteries in the absence of PVAT, first-order resistance arteries from the gracilis muscle were isolated from lean C57BL/6 mice. After dissection, resistance arteries were placed in a pressure myograph, cannulated, and studied at a pressure of 50 mmHg and a temperature of 37°C in K-MOPS buffer, as described previously (16). In addition to the resistance artery itself, PVAT that surrounds the resistance artery was isolated from the origin of the gracilis resistance artery at the femoral artery to its major side branch (Fig. 1A). PVAT derived from the same stretch of the resistance artery in C57BL/6 mice was also isolated from db/db mice. To study the interaction between PVAT and insulin-induced vasoreactivity of isolated resistance arteries, PVAT was coin-cubated with resistance arteries in the pressure myograph for 45 min (Fig. 1B). Resistance arteries were randomly assigned to incubation without PVAT (n = 9), C57BL6 PVAT (n = 10), or db/db PVAT (n = 8) of approximately equal amounts. After incubation, the inner diameter of resistance arteries was recorded to determine the baseline diameter after preconstriction to ~50% with KCl (25 mmol/L), and diameter changes induced by four concentrations of insulin (0.02, 0.2, 2.0, and 20 mmol/L, Actrapid; Novo Nordisk) were examined for 30 min (16). The three lowest concentrations of insulin are within the physiological range, with the third concentration (2.0 mmol/L) corresponding to postprandial levels and the fourth concentration to pharmacological levels. Endothelial integrity was determined by measuring responses to the endothelium-dependent vasodilator acetylcholine (0.1 μmol/L) after each experiment, with a minimum dilation of 10% used as proof of endothelial integrity.

Moreover, it was investigated whether reducing concentrations of adiponectin would affect insulin-induced vasoreactivity in resistance arteries from C57BL/6 mice with PVAT from C57BL/6 mice (n = 6). A soluble receptor fragment (Acpr-30 [N-20]-P adiponectin receptor blocking peptide; Santa Cruz Biotechnology) (0.4 μg/mL), which binds adiponectin, was preincubated in the pressure myograph for 30 min. Additionally, global adiponectin (Enzo Life Sciences, Antwerp, Belgium) was preincubated for 45 min in the vessel bath of the pressure myograph at a concentration of 1 μg/mL with C57BL6 resistance arteries without PVAT (n = 5) to investigate whether adiponectin can affect insulin-induced vasoreactivity when added from outside the resistance artery. Global adiponectin was also incubated in the presence of db/db PVAT (n = 7) to study whether it could restore insulin-induced vasodilation. As a model to inhibit downstream adiponectin signaling, the effects of the AMPK inhibitor Compound C (1 μmol/L, product number 171209; Calbiochem) on insulin-induced vasoreactivity were examined in C57BL6 resistance arteries in the presence of C57BL6 PVAT (n = 7).

**Vasoreactivity in resistance arteries of AMPKα2−−/− mice.** To further study the role of AMPKα2 in the interaction between PVAT and insulin-induced vasoreactivity, resistance arteries from AMPKα2−− and AMPKα2−+/+ mice were collected using the same techniques. Resistance arteries of AMPKα2−− (n = 8) and AMPKα2−+/+ (n = 6) were mounted in the pressure myograph and incubated with PVAT from AMPKα2−− mice for 45 min. After incubation, inner diameter and responses to insulin and acetylcholine were studied as described above. **Vasoreactivity experiments studying inflammatory properties of PVAT.** To study whether inflammatory adipokines are involved in the regulation of insulin-induced vasoreactivity by PVAT, we tested whether one phenotype of
PVAT would prevail during dual incubation with both C57BL/6 and db/db PVAT (n = 6).

Pressure myography was used to test whether acute inhibition of inflammation using L-JNKi (L-JNKi 1 trifluoracetate salt, 5 μmol/L; Sigma Aldrich, St. Louis, MO, USA) could restore vasodilator properties of db/db PVAT (n = 6). Furthermore, the soluble adiponectin receptor fragment (Acrp-30 [N-20]-P adiponectin receptor-blocking peptide, 0.4 μg/mL; Santa Cruz Biotechnology) was coincubated with L-JNKi in experiments with db/db PVAT to test whether the restored vasodilation by L-JNKi was mediated by adiponectin (n = 6).

Western blot. In order to investigate the effects of C57BL/6 and db/db PVAT on downstream insulin signaling in resistance arteries, Western blot analysis was performed as previously described (16). After 45 min incubation in the presence of PVAT from C57BL/6 or db/db mice, segments of gracilis arteries from C57BL/6 mice were exposed to solvent or insulin (2 nmol/L) for 30 min at 37°C. To investigate whether JNK inhibition restored insulin-mediated Akt phosphorylation in gracilis arteries exposed to db/db PVAT, other arterial segments, exposed to C57BL/6 or db/db PVAT, were exposed to insulin or solvent after pretreatment with L-JNKi. The protein lysates of resistance artery segments were stained with a specific primary antibody against Ser 473-phosphorylated Akt and threonine 172-phosphorylated AMPKα (antibodies from Cell Signaling Technology, Boston, MA) and were visualized with a chemiluminescence kit (GE Healthcare, Diegem, Belgium). As protein yields from gracilis muscle resistance arteries are low (<2 μg), and we were not able to stain AMPKα after stripping, we avoided stripping and reprobing blots. To obviate this, we used ERK1 as a loading control instead of total Akt or AMPKα. ERK1 correlates well with total Akt levels (27). As all experiments were paired and the duration of experiments was 1.5 h in total, differences in protein levels of Akt and AMPKα between experimental conditions are unlikely.

Adiponectin secretion (ELISA). To study whether PVAT from lean C57BL/6 mice secretes more adiponectin than PVAT from db/db mice, the amount of secreted adiponectin was quantified. PVAT isolated from lean (n = 7) and db/db (n = 7) mice, in amounts of comparable size, was incubated with 2 nmol/L insulin for 45 min at 37°C in order to study the release of adiponectin. Adiponectin concentration in conditioned medium was measured with a mouse adiponectin ELISA kit (Millipore, Amsterdam, the Netherlands) and detected using the Luminex system.

Statistics. Study-state responses are reported as mean change from baseline (percentages) ± SEM. Baseline diameter was determined as the diameter just prior to the addition of the first concentration of insulin. Statistical analyses for differences in insulin-induced vasoreactivity were performed using one-way ANOVA with Bonferroni post hoc tests, or Mann-Whitney U test where appropriate. Differences in protein phosphorylation, as found by Western blot, were determined using the Wilcoxon signed rank test. Phosphorylation was expressed as the fold increase over the unstimulated controls, assigning a value of 1 to the control. Differences with P values <0.05 were considered statistically significant.

RESULTS

Intramuscular PVAT weight is increased in db/db mice. PVAT was located around the resistance arteries, as well as A1 and A2 arterioles, in the muscle microcirculation (Fig. 1A). The weight of PVAT was higher in the db/db mice (1,365 ± 451 μg) than in lean C57BL/6 mice (333 ± 66 μg; P < 0.01) (Fig. 2B).

Intramuscular PVAT from lean C57BL/6 mice, but not db/db mice, uncovers insulin-induced vasodilation. Baseline vessel tone was not affected in resistance arteries by either C57BL/6 PVAT or db/db PVAT, nor was acetylcholine-induced vasodilation (Fig. 3A and B). Resistance arteries from C57BL/6 mice in the absence of PVAT did not show vasodilation or vasoconstriction in response to insulin (2 nmol/L; 0 ± 9%). After incubation with PVAT from C57BL/6 mice, insulin induced significant vasodilation (2 nmol/L; 52 ± 21%; P < 0.02 compared with baseline and < 0.05 vs. resistance arteries without PVAT) (Fig. 3C).

The vasodilation to insulin observed in the presence of C57BL/6 PVAT was completely abrogated when PVAT from db/db mice was used (2 nmol/L; -5 ± 3%; P < 0.02 compared with C57BL/6 PVAT) (Fig. 3D). To further study the insulin-induced vasodilator pathway, which is mediated through Akt and eNOS phosphorylation, phosphorylation of Akt was studied in the presence of C57BL/6 or db/db PVAT. The phosphorylation of Akt was significantly increased after insulin stimulation in resistance arteries of C57BL/6 mice in the presence of C57BL/6 as well as db/db PVAT. In the presence of C57BL/6 PVAT, the increase in Akt phosphorylation was significantly higher (P < 0.01 vs. db/db PVAT) (Fig. 3E).

Adiponectin from intramuscular PVAT mediates PVAT regulation of insulin-induced vasodilation and is reduced in db/db mice. To elucidate the mechanisms involved in the interaction of intramuscular PVAT with insulin-induced vasoreactivity, we examined the role of adiponectin in this interaction. Adiponectin was secreted more abundantly by PVAT from C57BL/6 mice (502 ± 115 pg/mL medium) than by PVAT from db/db mice (178 ± 33 pg/mL; P = 0.02) (Fig. 4A). When adiponectin was scavenged with a soluble adiponectin receptor fragment, Acrp-30 [N-20]-P, so that the db/db PVAT situation was mimicked, insulin-induced vasodilation was abolished (2 nmol/L; -19 ± 10%; P < 0.01 vs. C57BL/6 resistance arteries in the presence of PVAT). This indicates the importance of adiponectin from PVAT in insulin-induced vasodilation (Fig. 4B). Adiponectin, in the absence of PVAT, stimulated insulin-induced vasodilation in C57BL/6 resistance arteries (2 nmol/L; 21 ± 4%; P = 0.02 vs. C57BL/6 resistance arteries without PVAT) (Fig. 4C). Moreover, we incubated globular adiponectin in the presence of db/db PVAT (n = 7) to study whether supplementation of adiponectin could restore insulin-induced vasoreactivity. Adiponectin, in the presence of db/db PVAT, stimulated insulin-induced vasodilation 17 ± 4% (P < 0.01 compared with db/db PVAT alone) (Fig. 4D).
FIG. 3. The effects of C57BL/6 and db/db PVAT on basal tone, acetylcholine-induced vasoreactivity, insulin-induced vasoreactivity, and the insulin-signaling pathway, as well as the amount of adiponectin secretion. A: PVAT from either C57BL/6 or db/db mice does not affect smooth muscle tone of isolated resistance arteries (RAs) (white bar, tone in the absence of PVAT [n = 6]; black bar, tone in the presence of C57BL/6 PVAT [n = 5]; hatched bar, tone in the presence of db/db PVAT [n = 7]). Dmax, maximal diameter. B: PVAT from either C57BL/6 or db/db mice does not affect acetylcholine (ACh) 10^{-7}–induced vasodilation, indicating that there is no general microvascular dysfunction (white bar, acetylcholine-dependent vasodilation without PVAT [n = 5]; black bar, acetylcholine-dependent vasodilation in the presence of C57BL/6 PVAT [n = 4]; hatched bar, acetylcholine-dependent vasodilation in the presence of db/db PVAT [n = 6]). C: Insulin-induced vasoreactivity in the absence and presence of PVAT from control mice. C57BL/6-PVAT unveils insulin-induced vasodilation, which is not present in the absence of PVAT (white squares, C57BL/6 RA, without PVAT [n = 9]; black squares, C57BL/6 RA in the presence of C57BL/6 PVAT [n = 10]). D: Insulin-induced vasoreactivity in the presence of PVAT from C57BL/6 or db/db mice. PVAT from db/db mice does not unveil the vasodilator properties of insulin as PVAT from control mice does (black squares, C57BL/6 RA in the presence of C57BL/6 PVAT [n = 10]; white circles, C57BL/6 RA in the presence of db/db PVAT [n = 8]). E: Western blot of Akt phosphorylation initiated by insulin in RAs in the presence of C57BL/6 PVAT or db/db PVAT. Insulin causes a more pronounced Akt phosphorylation in the presence of C57BL/6 PVAT than in the presence of db/db PVAT. *P < 0.05 compared with no insulin; #P < 0.05 compared with C57BL/6 PVAT.
AMPK mediates control of insulin-induced vasodilation by PVAT in muscle. As AMPK is an important effector of adiponectin in vascular endothelium, we next examined the role of AMPK in the interaction of PVAT with insulin-induced vasoreactivity in isolated resistance arteries. Resistance arteries from C57BL/6 incubated with both PVAT from lean mice and compound C showed (9.64% at 2 nmol/L of insulin) vasodilation, a nonsignificant reduction (P = 0.28 vs. C57BL/6 resistance arteries with C57BL/6 PVAT) (Fig. 5A). However, there was no significant vasodilation compared with resistance arteries without PVAT.

AMPK phosphorylation was significantly increased in vessels exposed to both C57BL/6 PVAT (P = 0.006) and db/db PVAT (P = 0.028), compared with C57BL/6 resistance arteries without PVAT. There was, however, no difference in AMPK phosphorylation between vessels exposed to C57BL/6 PVAT and db/db PVAT (Fig. 5B). Deletion of AMPKα2 in muscle resistance arteries disturbs insulin-induced vasoreactivity in the presence but not the absence of PVAT. To further examine the role of AMPK in insulin-induced vasodilation induced by PVAT, resistance arteries from AMPKα2−/− mice were exposed to PVAT from AMPKα2+/− mice. Resistance arteries from AMPKα2−/− littermates served as controls. In the latter group, unlike the parallel studies using arteries and PVAT from C57BL/6 mice, insulin did not induce a significant vasodilation (2 nmol/L; 2.36%). There was no difference in insulin-induced vasoreactivity between AMPKα2−/− and AMPKα2+/− resistance arteries; both exhibited a neutral response (Fig. 5C).

However, AMPKα2−/− resistance arteries with AMPKα2+/− PVAT exhibited vasoconstriction (2 nmol/L; −26 ± 6%; P = 0.010) (Fig. 5D), pointing to strain differences with C57BL/6 mice. This indicates the importance of AMPK in the interaction between PVAT and insulin-induced vasodilation. Tone development and acetylcholine-induced vasodilation were not different between the two groups (Fig. 5E and F).

JNK inhibition restores insulin-induced, adiponectin-dependent vasodilation in the presence of db/db PVAT. Because Akt phosphorylation in the presence of db/db PVAT was lower (Fig. 3E) and AMPK phosphorylation is not different between C57BL/6 and db/db PVAT (Fig. 5B), adipokines other than adiponectin may also play...
a role in the change of insulin-induced vasodilation with db/db PVAT. To study whether PVAT from the muscle microcirculation produces additional vasoactive adipokines, incubation of a C57BL/6 resistance artery with C57BL/6 PVAT as well as db/db PVAT was performed (Fig. 6A). Dual incubation led to insulin-induced vasodilation (26 ± 9%; P < 0.05 vs. db/db PVAT). The vasodilation with dual PVAT incubation was smaller, however, than in the presence of C57BL/6 PVAT alone (P = NS) (Fig. 6A), suggesting interaction between the effects of C57BL/6 and db/db PVAT.

The vasodilator effect that was absent with db/db PVAT was restored by inhibiting inflammation using the JNK-inhibitor L-JNKi (2 nmol/L insulin; 48 ± 17%; P < 0.001 compared with db/db PVAT) and overlapping with the line of C57BL/6 PVAT, indicating that inflammation in either db/db PVAT or the acceptor resistance artery plays a role (Fig. 6B). Therefore, JNK opposes adiponectin-dependent vasodilator properties of PVAT in db/db mice.

When adiponectin was blocked during incubation with db/db PVAT and L-JNKi, the insulin-induced vasodilation was completely inhibited (2 nmol/L; 1 ± 6%; P < 0.01 vs. L-JNKi with db/db PVAT) (Fig. 6C). Treatment with L-JNKi did not restore insulin-stimulated Akt phosphorylation in the gracilis resistance arteries exposed to db/db PVAT (P = NS vs. the non-pretreated resistance arteries) (Fig. 6D).
DISCUSSION
The principal findings of this study are that 1) PVAT uncovers insulin-induced vasodilation in muscle resistance arteries by secreting adiponectin and activating AMPKα2 in the vessel wall, 2) in obese db/db mice, PVAT dramatically increases in muscle and loses its ability to induce insulin-mediated vasodilation, 3) this impaired interaction of PVAT with muscle resistance arteries is caused by a decrease in adiponectin release by PVAT and impairment of insulin-stimulated Akt activation, and 4) the blunted insulin-induced vasodilation with db/db PVAT can be restored by inhibition of JNK.

We show a direct regulatory effect of PVAT on insulin-induced vasoreactivity in muscle, shifting the balance of insulin’s vasoactive effects toward insulin-induced vasodilation. Our finding that PVAT controls vasoreactivity is in line with previous observations in the aorta and adipose tissue microvessels that PVAT controls vascular tone by antagonizing vasoconstriction in response to norepinephrine, endothelin-1, and angiotensin II (11,28,29). We did not observe an effect of PVAT on basal smooth muscle tone, indicating that the interaction of PVAT with insulin-induced vasoregulation is specific. As direct effects of

![Graph A](image1)

**FIG. 6.** A: Dual incubation of C57BL/6 PVAT and db/db PVAT partly restores insulin-induced vasodilation (black squares, C57BL/6 resistance artery [RA] with C57BL/6 PVAT [n = 10]; white circles, C57BL/6 RA with db/db PVAT [n = 8]; white squares, C57BL/6 RA with both C57BL/6 PVAT and db/db PVAT [n = 6]). *P < 0.05 vs. C57BL/6 RA + db/db PVAT. B: Inhibition of JNK with L-JNKi in a setup with a C57BL/6 RA and db/db PVAT returns insulin-induced vasodilation to levels comparable with C57BL/6 PVAT (black squares, C57BL/6 RA with C57BL/6 PVAT [n = 10]; white circles, C57BL/6 RA with db/db PVAT [n = 8]; white squares, C57BL/6 RA with db/db PVAT and L-JNKi [n = 6]). *P < 0.05 vs. C57BL/6 RA + db/db PVAT. C: The restoration of insulin-induced vasodilation by db/db PVAT with L-JNKi is mediated by adiponectin, because scavenging adiponectin completely abolishes this effect (black squares, C57BL/6 RA with C57BL/6 PVAT [n = 10]; white circles, C57BL/6 RA with db/db PVAT [n = 8]; white squares, C57BL/6 RA with db/db PVAT, L-JNKi, and the soluble adiponectin receptor fragment [n = 6]). *P < 0.05 vs. C57BL/6 RA with db/db PVAT + L-JNKi. D: L-JNKi does not restore Akt phosphorylation at Ser473 by insulin during exposure to db/db PVAT, whereas insulin does increase Akt phosphorylation at Ser473 during exposure to C57BL/6 PVAT. AU, arbitrary units. *P < 0.05.
PVAT on smooth muscle tone have been observed in adipose tissue and the aorta, the effects of PVAT on vasoregulation vary among different vascular beds.

We have shown that release of adiponectin and activation of AMPK by PVAT are critical to its control of insulin-induced vasoregulation in muscle. Previous studies have indeed shown that adiponectin can activate AMPK in endothelial cells (30), and previous data from our group have shown that adiponectin uncovers insulin-induced vasodilation in muscle resistance arteries through AMPK (31). Our data are in good agreement with the earlier data of Greenstein et al. (11) who showed that PVAT effects on norepinephrine-induced vascular tone in subcutaneous adipose tissue are mediated by adiponectin. Although PVAT releases adiponectin, and a soluble fragment of the adiponectin receptor 1 (AdipoR1) inhibited PVAT control of insulin-induced vasoregulation, a role of other adipokines in PVAT-endothelial communication cannot be completely excluded. The effect of PVAT on insulin-induced vasodilation was partially mimicked by recombinant globular adiponectin, even in the absence or presence of db/db PVAT as well as by dual incubation of db/db and C57BL/6 PVAT. This suggests that other adipokines than adiponectin play a supporting role or stimulate the insulin-induced vasoconstrictor pathway. Indeed, obesity seems to promote secretion of adipokines by PVAT that inhibit insulin-induced vasodilation and others that enhance insulin-induced vasconstriction, because the vasodilator effect of C57BL/6 PVAT was partially mimicked by adiponectin, and db/db PVAT decreases the vasodilator effect of C57BL/6 PVAT. Moreover, in AMPKα2/−/− mice, no insulin-induced vasodilation was observed with PVAT; however, knocking out AMPKα2 leads to insulin-induced vasoconstriction. This is further supported by equal amounts of AMPKα phosphorylation by C57BL/6 and db/db PVAT.

Although AMPK is an important effector of PVAT in vascular endothelium, we have observed AMPK-independent effects of PVAT. In AMPKα2-deficient resistance arteries, PVAT uncovers insulin-induced vasconstriction. Furthermore, PVAT from db/db mice enhances AMPKα phosphorylation in muscle resistance arteries but inhibits insulin-stimulated phosphorylation of Akt. These results suggest that AMPKα2 activation is a necessary, but not sufficient, step to uncover insulin-induced vasodilation. Moreover, db/db PVAT must regulate insulin’s vasoactive properties through a second mechanism, counteracting the insulin-induced vasodilation-stimulating effects of PVAT. The difference in net effects of PVAT between C57BL/6 and AMPKα2/−/− mice strongly suggests that genetic factors determine adipokine secretion by PVAT.

Indeed, inhibition of inflammation with L-JNKi fully restored the vasodilator capacity of db/db PVAT (Fig. 6B), whereas blocking adiponectin with the soluble adiponectin receptor fragment completely abrogated this effect (Fig. 6C). Inflammation therefore plays an important role in the defective PVAT properties of db/db mice. Interestingly, L-JNKi did not restore insulin-induced Akt phosphorylation during exposure to db/db PVAT (Fig. 6D). This finding may be explained by increased adiponectin secretion by db/db PVAT during JNK inhibition, or inhibition of insulin’s vasoconstrictor effects, which are independent from Akt (27). Indeed, inflammation of PVAT leads to a loss of its anticontractile properties (11,32). Nevertheless, adipokines other than adiponectin likely contribute to vasodilator effects of PVAT, as supplementation of adiponectin to db/db PVAT could not completely restore insulin-induced vasodilation (Fig. 4D).

Recently, a new class of adipokines, C1q/tumor necrosis factor (TNF)-related proteins, has been shown to activate AMPK in endothelial cells through the adiponectin receptor AdipoR1 (33). These C1q/TNF-related proteins could explain the AMPK phosphorylation and the vasodilator response to anti-inflammatory treatment with L-JNKi in the absence of increased Akt phosphorylation. The PVAT-derived adipokine that activates JNK in the muscle microcirculation remains to be identified in future studies. We have assessed secretion of the JNK agonists TNF-α and free fatty acids by muscle-derived PVAT but found only minor secretion of these adipokines (R.I.M., unpublished data). This finding does not exclude an autocrine role of TNF-α in regulating PVAT function.

Perspectives. Our results yield two novel insights into the pathogenesis of insulin resistance. First, we have shown that local depots of PVAT, which surround the resistance arteries in the muscle microcirculation, are capable of controlling insulin-dependent microvascular function. In humans, local accumulation of adipose tissue in the extremities is related to flow-mediated vasodilation and insulin sensitivity (21,34). These observations and the present dataset support our previous proposition (9) that adipokine-induced microvascular dysfunction in obesity is a paracrine, rather than an endocrine, process (9,35). In contrast to our initial hypothesis (9), we have found that altered adipokine secretion by intramuscular PVAT, rather than the formation of previously absent PVAT in muscle, impairs insulin-induced vasoregulation in obesity. Also, anti-inflammatory treatment restores insulin-induced vasodilation, at least partly, through adiponectin.

Second, our results provide a novel mechanism by which AMPK regulates insulin sensitivity. AMPK is well known as a “metabolic gauge” that controls both basal and insulin-stimulated glucose uptake (36). Paradoxically, AMPKα2 controls muscle insulin sensitivity in vivo but not in isolated muscles (26). Our observation that AMPKα2/−/− mice show impaired insulin-induced vasoregulation in the presence of PVAT, in combination with recent evidence that insulin-induced vasoregulation controls insulin sensitivity (2), suggests that AMPKα2 controls muscle insulin sensitivity by interacting with insulin-induced microvascular recruitment. Further support for this notion comes from our recent observation that AMPK activation by AICA-ribose enhances muscle microvascular blood volume (15).

In conclusion, in this study, we show that PVAT unveils vasodilator responses to insulin through the secretion of adiponectin, which is antagonized in db/db PVAT by the inflammatory kinase JNK. Adiponectin activates AMPKα2, which subsequently shifts the balance between vasodilation and vasoconstriction toward vasodilation. In obesity, the quantity of PVAT increases and adiponectin secretion diminishes. Due to the diminished adiponectin secretion and inflammatory burden, insulin no longer induces vasodilation. However, the insulin-stimulated vasodilation can be restored by inhibition of JNK.

ACKNOWLEDGMENTS
This research is sponsored by the Netherlands Heart Foundation (Grant 2009B008), the Netherlands Organization for Scientific Research (Grant 916.76.179), and the Danish Medical Research Council.
No potential conflicts of interests relevant to this article were reported.

R.I.M. wrote the manuscript and researched and analyzed data. W.B. and C.-L.A.F.A. researched data and edited the manuscript. P.S. and E.A.R. supervised and edited the manuscript. J.S.Y., Y.M.S., V.W.M.v.H., and E.H.S. supervised, contributed to discussions, and edited the manuscript. B.V. created the manuscript. E.C.E. researched data, supervised, contributed to discussions, and edited the manuscript. E.C.E. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in poster form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.

REFERENCES

1. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772–783
2. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294–307
3. Seré EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension 2007;50:204–211
4. Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetesologia 2009;52:752–764
5. Anderson TJ, Charbonneau F, Title LM, et al. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation 2011;123:163–169
6. Bakker W, Eringa EC, Sipkema P, van Hinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2006;325:155–168
7. Eringa EC, Bakker W, Smulders YM, Seré EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 2007;14:389–402
8. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006;55:1436–1442
9. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817–1820
10. Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res 2009;104:541–549
11. Greenstein AS, Khavandi K, Withers SB, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 2009;119:1661–1670
12. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008;114:361–374
13. Tschirhart O, Frötsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003;52:238–243
14. Busse CT, Kolka CM, Rattigan S, Richards SM. Adiponectin opposes endothelin-1-mediated vasconstriction in the perfused rat hindlimb. Am J Physiol Heart Circ Physiol 2011;301:H79–H86
15. Bradley EA, Eringa EC, Stehouwer CD, et al. Activation of AMP-activated protein kinase by 5-aminomidazole-4-carboxamide-1-beta-D-ribofurano-side in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. Arterioscler Thromb Vasc Biol 2010;30:1137–1142
16. Bakker W, Sipkema P, Stehouwer CDA, et al. Protein kinase C theta activation induces insulin-mediated constriction of muscle resistance arteries. Diabetes 2008;57:764–773
17. Youl JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes 2000;49:1904–1909
18. Clark LH, Rattigan S, Clark MG. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 2002;51:1138–1145
19. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 2009;296:E1210–E1229
20. Meijer RI, Serne EH, Smulders YM, van Hinsbergh VW, Yudkin JS, Eringa EC. Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease. Curr Diab Rep 2011;11:211–217
21. Röting K, Staib K, Machann J, et al. Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia 2008;51:2039–2049
22. Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460–2466
23. Gálvez B, de Castro J, Herold D, et al. Perivascular adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. Arte- rioscler Thromb Vasc Biol 2006;26:1297–1302
24. Gao YJ, Lu C, Su LY, Sharma AM, Lee RM. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007;151:323–331
25. Ma L, Ma S, He H, et al. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertension Res 2010;33:446–455
26. Viollet B, Andreff F, Jørgensen SB, et al. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J Clin Invest 2003;111:91–98
27. Eringa EC, Stehouwer CD, Walburg K, et al. Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-alpha dependence on e-NOS N-terminal kinase. Arterioscler Thromb Vasc Biol 2006;26:274–280
28. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 2009;54:1384–1392
29. Duhovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release from rat aortic adventitial adipose tissue. Am J Physiol Heart Circ Physiol 2004;286:H1107–H1113
30. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004;279:1304–1309
31. Eringa EC, de Boer MP, Bakker W, et al. Adiponectin uncovers insulin-mediated vasodilation by activating AMPK in microvascular endothelium and inhibiting insulin’s vasoinhibitor effects. Diabetes 2008;57:A385 [Abstract]
32. Withers SB, Agabiti-Rosei C, Livingstone DM, et al. Macrophage activation is responsible for loss of contractile function in inflamed perivascular fat. Arterioscler Thromb Vasc Biol 2011;31:908–913
33. Zheng Q, Yuan Y, Yi W, et al. ClayTFN-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/ AMPKεNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol 2011;31:2616–2623
34. Albu JB, Kovera AJ, Allen L, et al. Independent association of insulin resistance with larger amounts of intermuscular adipose tissue and a greater acute insulin response to glucose in African American than in white nonobese women. Am J Clin Nutr 2005;82:1210–1217
35. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:481–492
36. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 2009;418:261–275